tetano
Editor, Senior Moderator
PLoS One. 2019 Oct 23;14(10):e0223692. doi: 10.1371/journal.pone.0223692. eCollection 2019. [h=1]Elevated serum alpha-1 antitrypsin is a major component of GlycA-associated risk for future morbidity and mortality.[/h]
Ritchie SC[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Kettunen J[SUP]4,[/SUP][SUP]5,[/SUP][SUP]6[/SUP], Brozynska M[SUP]1,[/SUP][SUP]2[/SUP], Nath AP[SUP]1,[/SUP][SUP]2[/SUP], Havulinna AS[SUP]5,[/SUP][SUP]7[/SUP], M?nnist? S[SUP]5[/SUP], Perola M[SUP]5,[/SUP][SUP]7[/SUP], Salomaa V[SUP]5[/SUP], Ala-Korpela M[SUP]4,[/SUP][SUP]6,[/SUP][SUP]8,[/SUP][SUP]9,[/SUP][SUP]10,[/SUP][SUP]11[/SUP], Abraham G[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]12[/SUP], W?rtz P[SUP]13,[/SUP][SUP]14[/SUP], Inouye M[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]12,[/SUP][SUP]15[/SUP].
[h=3]Author information[/h] 1 Cambridge Baker Systems Genomics Initiative, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia. 2 Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. 3 Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia. 4 Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland. 5 National Institute for Health and Welfare, Helsinki, Finland. 6 NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 7 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. 8 Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom. 9 Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom. 10 Systems Epidemiology Lab, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia. 11 Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia. 12 School of BioSciences, The University of Melbourne, Parkville, Victoria, Australia. 13 Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 14 Nightingale Health Ltd, Helsinki, Finland. 15 The Alan Turing Institute, London, United Kingdom.
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] GlycA is a nuclear magnetic resonance (NMR) spectroscopy biomarker that predicts risk of disease from myriad causes. It is heterogeneous; arising from five circulating glycoproteins with dynamic concentrations: alpha-1 antitrypsin (AAT), alpha-1-acid glycoprotein (AGP), haptoglobin (HP), transferrin (TF), and alpha-1-antichymotrypsin (AACT). The contributions of each glycoprotein to the disease and mortality risks predicted by GlycA remain unknown.
[h=4]METHODS:[/h] We trained imputation models for AAT, AGP, HP, and TF from NMR metabolite measurements in 626 adults from a population cohort with matched NMR and immunoassay data. Levels of AAT, AGP, and HP were estimated in 11,861 adults from two population cohorts with eight years of follow-up, then each biomarker was tested for association with all common endpoints. Whole blood gene expression data was used to identify cellular processes associated with elevated AAT.
[h=4]RESULTS:[/h] Accurate imputation models were obtained for AAT, AGP, and HP but not for TF. While AGP had the strongest correlation with GlycA, our analysis revealed variation in imputed AAT levels was the most predictive of morbidity and mortality for the widest range of diseases over the eight year follow-up period, including heart failure (meta-analysis hazard ratio = 1.60 per standard deviation increase of AAT, P-value = 1?10-10), influenza and pneumonia (HR = 1.37, P = 6?10-10), and liver diseases (HR = 1.81, P = 1?10-6). Transcriptional analyses revealed association of elevated AAT with diverse inflammatory immune pathways.
[h=4]CONCLUSIONS:[/h] This study clarifies the molecular underpinnings of the GlycA biomarker's associated disease risk, and indicates a previously unrecognised association between elevated AAT and severe disease onset and mortality.
PMID: 31644575 DOI: 10.1371/journal.pone.0223692
Free full text
Ritchie SC[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Kettunen J[SUP]4,[/SUP][SUP]5,[/SUP][SUP]6[/SUP], Brozynska M[SUP]1,[/SUP][SUP]2[/SUP], Nath AP[SUP]1,[/SUP][SUP]2[/SUP], Havulinna AS[SUP]5,[/SUP][SUP]7[/SUP], M?nnist? S[SUP]5[/SUP], Perola M[SUP]5,[/SUP][SUP]7[/SUP], Salomaa V[SUP]5[/SUP], Ala-Korpela M[SUP]4,[/SUP][SUP]6,[/SUP][SUP]8,[/SUP][SUP]9,[/SUP][SUP]10,[/SUP][SUP]11[/SUP], Abraham G[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]12[/SUP], W?rtz P[SUP]13,[/SUP][SUP]14[/SUP], Inouye M[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]12,[/SUP][SUP]15[/SUP].
[h=3]Author information[/h] 1 Cambridge Baker Systems Genomics Initiative, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia. 2 Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. 3 Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia. 4 Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland. 5 National Institute for Health and Welfare, Helsinki, Finland. 6 NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 7 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. 8 Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom. 9 Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom. 10 Systems Epidemiology Lab, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia. 11 Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia. 12 School of BioSciences, The University of Melbourne, Parkville, Victoria, Australia. 13 Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 14 Nightingale Health Ltd, Helsinki, Finland. 15 The Alan Turing Institute, London, United Kingdom.
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] GlycA is a nuclear magnetic resonance (NMR) spectroscopy biomarker that predicts risk of disease from myriad causes. It is heterogeneous; arising from five circulating glycoproteins with dynamic concentrations: alpha-1 antitrypsin (AAT), alpha-1-acid glycoprotein (AGP), haptoglobin (HP), transferrin (TF), and alpha-1-antichymotrypsin (AACT). The contributions of each glycoprotein to the disease and mortality risks predicted by GlycA remain unknown.
[h=4]METHODS:[/h] We trained imputation models for AAT, AGP, HP, and TF from NMR metabolite measurements in 626 adults from a population cohort with matched NMR and immunoassay data. Levels of AAT, AGP, and HP were estimated in 11,861 adults from two population cohorts with eight years of follow-up, then each biomarker was tested for association with all common endpoints. Whole blood gene expression data was used to identify cellular processes associated with elevated AAT.
[h=4]RESULTS:[/h] Accurate imputation models were obtained for AAT, AGP, and HP but not for TF. While AGP had the strongest correlation with GlycA, our analysis revealed variation in imputed AAT levels was the most predictive of morbidity and mortality for the widest range of diseases over the eight year follow-up period, including heart failure (meta-analysis hazard ratio = 1.60 per standard deviation increase of AAT, P-value = 1?10-10), influenza and pneumonia (HR = 1.37, P = 6?10-10), and liver diseases (HR = 1.81, P = 1?10-6). Transcriptional analyses revealed association of elevated AAT with diverse inflammatory immune pathways.
[h=4]CONCLUSIONS:[/h] This study clarifies the molecular underpinnings of the GlycA biomarker's associated disease risk, and indicates a previously unrecognised association between elevated AAT and severe disease onset and mortality.
PMID: 31644575 DOI: 10.1371/journal.pone.0223692
Free full text